Antiproliferative and c-myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture
- PMID: 8799562
- PMCID: PMC1909533
- DOI: 10.1111/j.1476-5381.1996.tb15486.x
Antiproliferative and c-myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture
Abstract
1. Newborn human vascular smooth muscle cells (VSMCs) proliferated faster and were more sensitive to platelet-derived growth factor-BB (PDGF-BB) than those from adults. In this study, we investigated mechanism of the inhibitory effect of tranilast on PDGF-BB-induced proliferation of VSMCs from newborns. 2. Tranilast (30-300 microM) concentration-dependently inhibited the VSMC proliferation in randomly growing cultures stimulated with PDGF-BB. 3. Tranilast (30-300 microM) concentration-dependently inhibited the [3H]-thymidine incorporation into DNA in VSMCs that had been synchronized by 48 h serum depletion and then stimulated by addition of PDGF-BB. However, tranilast had little influence on unscheduled DNA synthesis in quiescent cells or on RNA and protein synthesis, unlike aphidicolin, actimomycin D, and cycloheximide. 4. In synchronized VSMC cultures, tranilast still inhibited the PDGF-BB-induced DNA synthesis even when added 18 h after stimulation of the quiescent cells. The mode of the antiproliferative action of tranilast was different from that of NiCl2, genistein, or staurosporin. In addition, flow cytometry of synchronized VSMCs treated with tranilast revealed a blockade of PDGF-inducible cell-cycle progression at the G1/S checkpoint. 5. Northern blotting showed that tranilast (30-300 microM) concentration-dependently suppressed constitutive c-myc mRNA expression even when added 18 h after PDGF-BB-stimulation of quiescent VSMCs. Tranilast still had an inhibitory effect on the induction of c-myc mRNA when de novo protein synthesis was inhibited by cycloheximide and did not shorten the degradation of c-myc mRNA at the post-transcriptional level, demonstrating that tranilast directly inhibited c-myc mRNA expression at the transcriptional level. 6. These results suggest that the inhibitory effect of tranilast on PDGF-BB-induced proliferation is due to S-phase blockade and may be, at least in part, involved in the direct suppression of c-myc gene expression. Tranilast did not cause cell toxicity and may therefore hold promising potential for the prevention of vascular proliferative diseases.
Similar articles
-
Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors.Br J Pharmacol. 2000 May;130(2):307-14. doi: 10.1038/sj.bjp.0703285. Br J Pharmacol. 2000. PMID: 10807667 Free PMC article.
-
Antiproliferative activity of NQ304, a synthetic 1,4-naphthoquinone, is mediated via the suppressions of the PI3K/Akt and ERK1/2 signaling pathways in PDGF-BB-stimulated vascular smooth muscle cells.Vascul Pharmacol. 2007 Jan;46(1):43-51. doi: 10.1016/j.vph.2006.06.007. Epub 2006 Jun 16. Vascul Pharmacol. 2007. PMID: 16875883
-
Cudratricusxanthone A isolated from the root bark of Cudrania tricuspidata inhibits the proliferation of vascular smooth muscle cells through the suppression of PDGF-receptor beta tyrosine kinase.Biol Pharm Bull. 2007 Apr;30(4):805-9. doi: 10.1248/bpb.30.805. Biol Pharm Bull. 2007. PMID: 17409526
-
Platelet-derived growth factor stimulated vascular smooth muscle cell proliferation and its molecular mechanism.Acta Pharmacol Sin. 2000 Apr;21(4):340-4. Acta Pharmacol Sin. 2000. PMID: 11324463
-
Antiproliferative effects of immunosuppressant drugs on vascular smooth muscle cells: an additional advantage for attenuating transplant vasculopathy.Drug News Perspect. 2004 Mar;17(2):110-6. doi: 10.1358/dnp.2004.17.2.829044. Drug News Perspect. 2004. PMID: 15098065 Review.
Cited by
-
Innovative therapies in the treatment of keloids and hypertrophic scars.J Clin Aesthet Dermatol. 2010 May;3(5):20-6. J Clin Aesthet Dermatol. 2010. PMID: 20725565 Free PMC article.
-
Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions.Adv Drug Deliv Rev. 2018 Jan 1;123:135-154. doi: 10.1016/j.addr.2017.07.017. Epub 2017 Jul 27. Adv Drug Deliv Rev. 2018. PMID: 28757325 Free PMC article. Review.
-
Suppression of the allogeneic response by the anti-allergy drug N-(3,4-dimethoxycinnamonyl) anthranilic acid results from T-cell cycle arrest.Immunology. 2013 Feb;138(2):157-64. doi: 10.1111/imm.12026. Immunology. 2013. PMID: 23121382 Free PMC article.
-
Biological Activities, Health Benefits, and Therapeutic Properties of Avenanthramides: From Skin Protection to Prevention and Treatment of Cerebrovascular Diseases.Oxid Med Cell Longev. 2018 Aug 23;2018:6015351. doi: 10.1155/2018/6015351. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 30245775 Free PMC article. Review.
-
Inhibitory mechanism of tranilast in human coronary artery smooth muscle cells proliferation, due to blockade of PDGF-BB-receptors.Br J Pharmacol. 2000 May;130(2):307-14. doi: 10.1038/sj.bjp.0703285. Br J Pharmacol. 2000. PMID: 10807667 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources